Wrapping up presentations at this years annual Liver Meetings in Boston, Dr. Eric Lawitz presented data on 2 new antiviral agents to treat chronic hepatitis C. This study looked at the more tough to treat populations. These two drugs use in cirrhotic patients and those prior null responder to Peg-intron and ribavirin had between a […]
by Dr. Joe Galati on 11/11/2014
by Dr. Joe Galati on 11/09/2014
A research paper presented this morning at the AASLD Liver Meeting indicates that liver donors 80 years of age and older do just as well as those receiving a liver transplant from a donor less than 80 years old. Considering the large number of patients awaiting liver transplant, and the associated limited number of suitable […]
by Dr. Joe Galati on 11/07/2014
As the treatments for chronic hepatitis C continue to expand, and provide a superior cure rate, the FDA has approved the combination of both Sovaldi(sofosbuvir) and Olysio (simeprevir) for treating HCV. We have been using this combination, but it was not officially approved, causing some insurance related issues for some patients. Here is one of […]
by Dr. Joe Galati on 10/23/2014
Harvoni, the newly FDA approved drug for chronic hepatitis C, is indicated for genotype 1 patients only. All others, at this time, are not approved. Additional new drugs are in the process of receiving FDA approval for the other genotypes. While there is no official indication for treating post-liver transplant patients, many experienced physicians will […]
by Dr. Joe Galati on 10/21/2014
More information on the new Gilead drug Harvoni for patients with hepatitis C.
by Dr. Joe Galati on 10/10/2014
Yet another hepatitis C drug has been approved by the FDA, a great day for those who suffer from hepatitis C. A combination of Ledipasvir and Sofosbuvir, this new drug, called Harvoni, is the latest entry by Gilead, leading the way in curing hepatitis C. For patients interested in therapy, contact our office during business […]
by Dr. Joe Galati on 07/06/2014
For full disclosure, I prefer mayo over mustard. Growing up, we were a mayo leaning household. Blame my parents. Sitting having lunch today, as I reached for my favorite mayonnaise, my eye focuses on the bottom of the bottle, with somewhat of a surprising health claim: my favorite “real” mayonnaise actually will supply me with […]
by Dr. Joe Galati on 07/05/2014
Our latest video covers the basic aspects of alcohol related liver disease, and the complications of excessive alcohol intake. In general, there are three areas of concern: 1. The development of alcoholic fatty liver disease 2. The development of acute alcoholic hepatitis 3. Alcoholic cirrhosis The major point to understanding is that all alcoholic drinks […]
by Dr. Joe Galati on 06/29/2014
Which that said, my estimate is that 35% of these young women are overweight or obese. This is consistent with the national trend. One of the players had a very obvious “spare tire” that was visually obvious with every swing. The gravity if this adipose tissue flung forward with the twist of her swing. With […]
by Dr. Joe Galati on 06/29/2014
Here is information on a recent radio segment I did discussing Alcohol Awareness Month, and the ill effects alcohol has on your body. Read it and share it with your family. Listen to the broadcast segment.
- Telaprevir and FDA Approval: The Race is On for New Hepatitis C Drugs 02/28/2011
- The MELD Score and Liver Transplant: An Update for Patients 02/02/2011
- Waiting for a Liver Transplant: My MELD Score is Low-Now What? 06/14/2012
- Grazoprevir and Elbasvir: New Hepatitis C Treatment Options with High Cure Rates 11/11/2014
- Liver Transplant with Donors Over 80 Years Old Do Well 11/09/2014
- Olysio and Sovaldi Now Approved for Hepatitis C 11/07/2014
- Chuck Garcia: On a recent stroll through the supermarket aisles,...
- K Beecher: Hello. My husband was 24 to 48 hours away from dy...
- Firdous Ahmad: Dear Dr, My mother have hepatitis C, and she also ...